Biotech IPOs and Mega-Follow-Ons Flood an Open Issuance Window

The window is open — wide open

August 2026 opened with a burst of primary issuance that would have been unthinkable in a higher-volatility environment. Six IPOs and five SPACs priced in the first full week of the month, joined by two of the largest follow-on equity offerings of the year. The Cboe Volatility Index (VIX) fell to its lowest level since January as the S&P 500 added 0.6% on Friday, bringing the week’s advance to 3.6%^[1]. Historically, a VIX below 15 opens the IPO window widely, while levels above 25 trigger a hard stop on new issuance^[1]. With the gauge plumbing multi-month lows and the S&P 500 at record highs, underwriters had the green light.

The result was a calendar that tells two stories at once: a biotech-led IPO surge testing investor appetite for clinical-stage risk, and a mega-cap follow-on wave tapping equity markets at premium valuations. Layered over both is a structural shift — the SEC’s June proposal to rescind Regulation NMS Rule 611, the trade-through prohibition that has governed US equity order routing for two decades. The combination of abundant issuance appetite and potential plumbing reform makes August a pivotal month for anyone watching how capital formation and market structure intersect.

Biotech IPOs: five clinical-stage companies test the market

The first week of August produced five biotech IPOs, all of which upsized or priced within their ranges — a signal that institutional demand for clinical-stage equity is genuinely broad, not merely headline-deep^[2].

Source: Renaissance Capital weekly recap, August 7, 2026^[2]

The standout was Braveheart Bio (BRVE), which upsized and priced above its range to raise $383 million at a $1.6 billion market cap and finished its first week up 67%^[2]. Its lead candidate, BHB-1893, is an oral cardiac myosin inhibitor licensed from China’s Hengrui Pharmaceuticals targeting both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM), with a global Phase 3 trial planned for the second half of 2026^[2].

Latigo Biotherapeutics (LTGO) raised $346 million at the top of its range, pricing 19.2 million shares at $18 — the high end^[3][2]. Its lead candidate, LTG-001, is an oral Nav1.8 inhibitor for moderate-to-severe acute pain, with Phase 3 trials planned for 2H26 and topline results expected in 2H27^[2].

Attovia Therapeutics (ATTO) raised $289 million at the high end of its range at a $767 million market cap, developing biologic therapies for immune-mediated diseases through its ATTOBODY platform. Its lead candidate, ATTO-1310, targets IL-31 for chronic pruritus and atopic dermatitis, with a Phase 2 trial planned for 1H27^[2].

BlossomHill Therapeutics (BLSM) priced its upsized IPO at the midpoint — $16 per share — raising $150 million at a $503 million fully-diluted market cap^[4]. Founded by the couple behind Turning Point Therapeutics (acquired by Bristol-Myers Squibb for $4 billion), BlossomHill is going after AstraZeneca’s blockbuster NSCLC drug Tagrisso with an EGFR TKI designed to overcome the C797S resistance mutation that develops in 13% of patients on third-generation TKIs^[4]. The company plans to seek an end-of-Phase 1 meeting with the FDA in 4Q26 to discuss a potential accelerated approval pathway, with a registrational Phase 2 trial beginning in 1Q27^[4].

The non-biotech entry was River City Bank (RCBC), a 1973-founded commercial bank serving Northern California, which priced a downsized IPO below its range to raise $122 million at a $637 million market cap. Its commercial real estate lending franchise accounts for roughly 90% of its loan portfolio^[2] — a concentration worth noting in the current CRE environment.

A sixth IPO, Latin American ticketing platform Ticketplus (TP), priced at the bottom of its range to raise just $15 million and finished the week down 13%, a reminder that not every deal clears^[2].

The follow-on wave: Celestica and Prologis lead $5.5 billion in secondary issuance

While IPOs captured the headlines, the follow-on market moved more capital by an order of magnitude.

Celestica (CLS) announced a $3 billion equity offering on August 5 to fund investments in its AI infrastructure business, then upsized and closed at $3.45 billion after underwriters exercised their overallotment option in full^[5][6]. The company sold 11.1 million shares at $310 per share — a 16.5% discount to its prior NYSE close^[6]. CFO Mandeep Chawla cited “accelerating momentum” and the need to “scale alongside our customers’ evolving multi-year capital deployment plans,” while CEO Rob Mionis called the demand outlook “the strongest in the Company’s history”^[5]. Net proceeds are earmarked for working capital and capital expenditures supporting Celestica’s 800G and 1.6T networking and AI/ML compute programs with data center customers^[5]. BofA Securities, Citigroup, and TD Securities led the underwriting^[6].

Prologis (PLD) priced a $2.1 billion common stock offering the day before, selling 15 million shares with J.P. Morgan and BofA Securities as underwriters, with an overallotment option that could push total proceeds to $2.4 billion^[7]. The industrial REIT is tapping the market as logistics real estate demand continues to benefit from e-commerce and supply-chain reconfiguration.

Smaller secondaries also moved through the pipeline. Primo Brands (PRMB) launched a 20 million-share secondary offering by an affiliate of One Rock Capital Partners^[8]. On August 11, Savers Value Village (SVV) announced a 15 million-share secondary offering by Ares Private Equity funds, paired with a $10 million concurrent buyback by the company; the stock fell 9.3% to $10.70 in after-hours trading^[9].

The combined first-week volume — roughly $5.5 billion in priced follow-on equity alone — demonstrates that the open window extends well beyond new listings. Issuers with existing public floats are capitalizing on elevated prices and low volatility to raise primary capital or allow existing holders to exit.

The structural backdrop: SEC proposes rescinding Reg NMS Rule 611

Beneath the issuance activity, the SEC’s June 11 proposal to rescind Regulation NMS Rules 611 and 610(e) continues to work its way through the public comment process^[10]. If adopted, it would represent the most significant equity market-structure reform in two decades.

Rule 611, adopted in 2005, prohibits “trade-throughs” — executions at prices inferior to protected quotations displayed on other exchanges. In practice, it hardwires the National Best Bid and Offer (NBBO) into transactions across all NMS stocks, requiring trading centers to route orders to venues displaying better prices^[11]. Rule 610(e) prohibits locked and crossed quotations across venues^[10].

The SEC’s rationale for rescission rests on three arguments^[10][11]:

1. Market evolution. When Rule 611 was adopted in 2005, eight national securities exchanges traded NMS stocks. Today there are 17 operating exchanges with three more approved, yet off-exchange venues — dark pools, ATSs, single-dealer platforms, and wholesalers — regularly exceed 50% of total volume^[11]. Rule 611 has incentivized exchange proliferation and connectivity costs while fragmenting liquidity.
2. Technological obsolescence. Trading is now electronic, routing is automated, and market data is widely available, allowing investors to monitor whether they receive the best available prices without the rule’s mandate^[11].
3. Deregulatory agenda. Chairman Paul Atkins framed the proposal within the SEC’s “Project Crypto” initiative, signaling the rescission could facilitate trading of tokenized securities on-chain by removing the structural incompatibility between Rule 611’s order-routing requirements and automated market makers (AMMs) used in DeFi protocols^[11].

If finalized, the governing framework would shift from Rule 611’s rigid intermarket protection to broker-level best execution under FINRA Rule 5310, which requires “reasonable diligence” to obtain the most favorable price under prevailing conditions — a standard more compatible with AMM-based trading because it can accommodate slippage and programmatic execution^[11].

The 60-day public comment period opened with Federal Register publication on June 17, 2026^[12], meaning comments are due in mid-August — placing the debate squarely within the current issuance cycle.

What to watch next

• Comment period close. The Reg NMS comment window closes in mid-August. Watch for institutional comment letters from major exchanges, broker-dealers, and ATS operators — the substance of objections will signal how contested adoption will be.
• Biotech aftermarket performance. Braveheart’s 67% first-week pop is the outlier; BlossomHill finished flat and Latigo up just 1%. Whether the clinical-stage names that priced quietly can sustain trading above their offer prices will determine whether the biotech window stays open through September.
• Lock-up releases. Renaissance Capital noted six IPO lock-up releases in the week ahead^[2]. Lock-up expirations can introduce selling pressure, particularly for recently volatile names. SpaceX (SPCX), which reported its first earnings as a public company during this period and faces a partial lock-up release that will more than double the tradable float^[13], is the marquee name to watch.
• Follow-on absorption. The market’s ability to digest $5.5 billion in secondary equity without sustained price disruption will signal whether the window has room to widen further. Watch for any pullback in Celestica and Prologis toward their offering prices as a gauge of absorption health.
• IPO index performance. The Renaissance IPO Index was up 18.8% year-to-date as of August 6, outpacing the S&P 500’s 13.4%^[2]. A continued premium for newly public companies sustains the incentive for private firms to file.
• Nasdaq liquidity-provider changes. Separately from the SEC proposal, Nasdaq filed for immediate effectiveness of amendments to its Designated Liquidity Provider and Market Quality Supporter programs^[14] — an incremental but meaningful adjustment to the microstructure that supports new listings.

FN2 Research provides market commentary and education, not personalized investment advice. All IPO pricing data and market-structure references are sourced from public filings and cited sources as of August 11, 2026.